Heat shock protein 65 immunoreactivity in experimentally induced polymorphic light eruption.
DOI:
https://doi.org/10.2340/0001555574286288Abstract
The expression of 65 kiloDalton heat shock protein (HSP65) immunoreactivity of skin biopsies from experimentally induced polymorphic light eruption (PLE) lesions was studied, to investigate its possible role as a photo-induced antigen responsible for precipitating lesions. In each subject the 24-h minimal erythema dose of solar simulated radiation was determined and an area of skin previously affected by PLE subjected to 70% of the minimal erythema dose in order to induce PLE lesions. The irradiated areas were sequentially biopsied between 0 and 6 days. ML-30, a monoclonal antibody which recognises heat shock protein 65, was used to label the sections by means of an indirect immunoperoxidase technique. In PLE patients clinical inflammation was noted by 5 h post-irradiation, with these were still present at 6 days. Increased ML-30 antibody labelling in epidermal keratinocyte and endothelial cell cytoplasm was recognisable from 1 h post-irradiation, and in dermal dendritic cells from 5 h sustained through to 6 days. In normal subjects neither clinical nor histological features of inflammation were noted after irradiation, nor any increase in HSP65 labelling. subsequent evolution of PLE-like lesionsDownloads
Downloads
Published
How to Cite
Issue
Section
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.